[Form 4] MacroGenics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.

Insights

Compensation Analyst

TL;DR: A large option grant aligns CEO incentives with long-term equity value but dilutes existing shareholders if exercised.

The 550,000-option award at a $1.66 strike creates a multi-year retention and upside-linked incentive for the CEO given the extended expiration to 2035 and staggered vesting. This structure is typical for executive compensation aiming to align management with shareholder value over time. Investors should note the absolute size of the grant relative to the company’s outstanding equity for dilution considerations; the filing reports direct beneficial ownership of 550,000 shares post-grant.

Corporate Governance Expert

TL;DR: Grant to an executive who is also a director raises routine governance questions about approval and disclosure but is a standard compensation practice.

The filing discloses role and direct ownership but does not include information about the approval process or whether the grant was part of a pre-existing plan or board action. The vesting schedule (25% after one year, then quarterly over three years) supports retention. The disclosure is specific on terms: 550,000 options, $1.66 exercise, exercisable through 08/13/2035, and direct ownership classification.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Risser Eric Blasius

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.66	08/13/2025		A		550,000		(1)	08/13/2035	Common Stock	550,000	$0	550,000	D

Explanation of Responses:

1. 25% of the options will vest and become exercisable one year from the grant date and the remaining 75% will vest in 12 substantially equal quarterly installments thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MacroGenics (MGNX) disclose about insider Eric Risser's transaction?

The filing reports an employee stock option grant of 550,000 shares to Eric Risser with an exercise price of $1.66 and an expiration date of 08/13/2035.

How does the vesting schedule work for the granted options?

The options vest 25% one year after grant and the remaining 75% vest in 12 substantially equal quarterly installments thereafter.

Is the beneficial ownership direct or indirect?

The filing lists the ownership form as Direct and shows 550,000 shares beneficially owned following the reported transaction.

What is the exercise price for the options granted to the CEO?

The exercise (strike) price disclosed in the filing is $1.66 per share.

When are the options exercisable until?

The options have an expiration date of 08/13/2035, as stated in the filing.